<DOC>
	<DOCNO>NCT02346890</DOCNO>
	<brief_summary>The study design evaluate safety , tolerability , pharmacodynamics pharmacokinetics AZD1722 healthy volunteer take Renvela .</brief_summary>
	<brief_title>A Phase 1 Study Examine Effect Renvela Pharmacodynamics AZD1722</brief_title>
	<detailed_description />
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Healthy man woman Body mass index 18 29.9 kg/m2 Diagnosis treatment clinically symptomatic biochemical structural abnormality gastrointestinal ( GI ) tract Any surgery small intestine colon , exclude appendectomy cholecystectomy condition know interfere absorption , distribution , metabolism excretion drug Clinical evidence significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematologic , metabolic , endocrine , neurologic , psychiatric disease , condition may interfere subject successfully complete trial would present safety risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Volunteer</keyword>
</DOC>